Simcere Pharmaceutical partners with Stanford on IPF therapy using LYTAC technology
Simcere Pharmaceutical partners with Stanford on IPF therapy using LYTAC technology to target protein degradation beyond current treatment limits.
Simcere Pharmaceutical partners with Stanford on IPF therapy using LYTAC technology to target protein degradation beyond current treatment limits.
VERAXA Biotech launches on Nasdaq with $77.5M financing for BiTAC Platform, designed to reduce toxicity in T-cell engagers for...
Neion Bio raises $23M Series A for egg-based protein manufacturing platform targeting recombinant biologics production.
Adial Pharmaceuticals acquires Azora Therapeutics for $64M to develop AT177, an indirubin prodrug targeting ulcerative colitis through localized colon...
BridgeBio partners with DKSH to distribute Attruby in Asia Pacific markets including Australia, Singapore, South Korea, and Taiwan.
Teva acquires Emalex for ecopipam, a D1 receptor drug with Phase 3 data showing efficacy in pediatric Tourette syndrome,...
Apollo Therapeutics appoints Timothy Walbert as chairman, signaling a shift toward commercial strategy for the biotech company's university-sourced pipeline.
Alembic acquires NUVESSA for bacterial vaginosis treatment, expanding its women's health portfolio with a single-dose metronidazole gel option.
Cartesian and WestGene partner on in vivo CAR-T for myasthenia gravis, combining mRNA payload with lipid nanoparticle delivery in...
Optimi Health secures ibogaine supply for U.S. clinical trials, leveraging Canadian manufacturing to address a research bottleneck amid accelerated...